Related references
Note: Only part of the references are listed.Epidemiology of Castleman Disease
David Simpson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C. Fajgenbaum
BLOOD (2018)
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy
David C. Fajgenbaum et al.
BLOOD (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
The clinical spectrum of Castleman's disease
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Surgery in Castleman's Disease A Systematic Review of 404 Published Cases
Nadia Talat et al.
ANNALS OF SURGERY (2012)
Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease
Frits van Rhee et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care
C Casper
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Share Paper
